Physician profile
Nicholas Patrick Harth
NPI 1205518420
$4,856.25
in general payments reported to CMS, 2019-2025
27 companies · $2,153 in 2025
The $2,153 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $252 · 2024: $2,452 · 2025: $2,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,856.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $854.78 | 2023-2025 | |
| Novo Nordisk INC | $664.22 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $517.71 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $406.70 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $402.60 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $334.51 | 2024-2025 | |
| Exact Sciences Corporation | $200.82 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.00 | 2024-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $167.89 | 2024-2025 | Eliquis, Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $135.26 | 2024-2025 | Xifaxan, Trulance |
| Axsome Therapeutics, INC. | $123.57 | 2023-2025 | Auvelity |
| Merck Sharp & Dohme LLC | $107.31 | 2023-2025 | Gardasil 9, Vaxelis, Capvaxive |
| Lundbeck LLC | $87.08 | 2024-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $86.93 | 2024-2025 | Trintellix |
| Novartis Pharmaceuticals Corporation | $86.63 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $78.58 | 2024-2025 | Rexulti |
| Dexcom, INC. | $74.76 | 2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $67.94 | 2024-2025 | Veozah |
| Amgen INC. | $55.92 | 2024 | Otezla, Repatha, Evenity |
| Phathom Pharmaceuticals, INC. | $45.50 | 2025 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $37.51 | 2025 | Austedo Xr |
| Verona Pharma, INC. | $36.50 | 2025 | Ohtuvayre |
| Sonex Health, INC. | $25.77 | 2025 | Sx-One Microknife |
| Inspire Medical Systems, INC. | $22.37 | 2024 | Inspire |
| Cequr Corporation | $20.24 | 2023-2024 | Cequr Simplicity |
| Vanda Pharmaceuticals INC. | $15.84 | 2025 | Fanapt |
| Idorsia Pharmaceuticals US INC | $14.31 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Harth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.